The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abnormal lipoprotein particles and cholesterol efflux capacity in patients with psoriasis
Open accessAbstract
Objectives Psoriasis is a Th-1/17 mediated inflammatory disease associated with increased risk of cardiovascular disease (CVD). Inflammation may modulate lipoprotein particle number and directly impair HDL functions, in particular reverse cholesterol transport (RCT). We sought to study how chronic in vivo inflammation modulates lipoprotein particle composition using nuclear magnetic resonance spectroscopy (NMR) and HDL efflux in psoriasis. Methods and Results We prospectively enrolled a consecutive sample of patients with psoriasis (n=122) and compared lipoprotein and metabolic risk factors to patients without psoriasis (n=134). Fasting lipids, insulin, glucose were measured by standard assays, and lipoprotein concentration and size were measured by NMR. In a random subset (n=100 each group), HDL efflux capacity was quantified using a validated ex vivo system involving the incubation of macrophages with apolipoprotein B-depleted serum from patients. Traditional lipid concentrations were similar in both groups except for HDL concentration which was lower in psoriasis (43 mg/dL (36–58) vs 50 (42–62), p<0.01). However, NMR showed an atherogenic profile in psoriasis similar to that observed in diabetes, with significant increase in LDL particle concentration [1210.5 (1002–1498) vs 1115 (935–1291), p=0.03] with decrease in LDL size [20.6 (20.3–21.1) vs 21.3 (20.6–21.1), p<0.001] beyond CV risk factors and HOMA-IR (p=0.001). Finally, HDL efflux capacity was lower in psoriasis compared to controls in fully adjusted models (beta −0.14, p=0.001). Conclusions These data support a more atherogenic lipoprotein profile by NMR and decreased HDL efflux capacity in psoriasis patients compared to controls beyond CVD risk factors. The abnormal lipoprotein particle composition and HDL efflux capacity in psoriasis may provide a link between psoriasis and CVD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effects of torcetrapib in patients at high risk for coronary events
Barter, P. J., Caulfield, M., Eriksson, M., Grundy, S. M., Kastelein, J. J. P., Komajda, M., Lopez-Sendon, J., Mosca, L., Tardif, J.-C., Waters, D. D., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706628 · Cited by 3,139
Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis
Khera, A. V., Cuchel, M., de la Llera-Moya, M., Rodrigues, A., Burke, M. F., Jafri, K., French, B. C., Phillips, J. A., Mucksavage, M. L., Wilensky, R. L., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1001689 · Cited by 1,943
Self-citationRisk of myocardial infarction in patients with psoriasis
Gelfand, J. M., Neimann, A. L., Shin, D. B., Wang, X., Margolis, D. J., & Troxel, A. B. (2006) · JAMA · doi:10.1001/jama.296.14.1735 · Cited by 1,899
Self-citation
Cited by
Psoriasis and comorbid diseases
Takeshita, J., Grewal, S., Langan, S. M., Mehta, N. N., Ogdie, A., Van Voorhees, A. S., & Gelfand, J. M. (2017) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2016.07.064 · Cited by 1,145
Self-citationElmets, C. A., Leonardi, C. L., Davis, D. M. R., Gelfand, J. M., Lichten, J., Mehta, N. N., Armstrong, A. W., Connor, C., Cordoro, K. M., Elewski, B. E., et al. (2019) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2018.11.058 · Cited by 503
Self-citationArmstrong, E. J., Harskamp, C. T., & Armstrong, A. W. (2013) · Journal of the American Heart Association · doi:10.1161/jaha.113.000062 · Cited by 470
Checa, A., Xu, N., Sar, D. G., Haeggström, J. Z., Ståhle, M., & Wheelock, C. E. (2015) · Scientific Reports · doi:10.1038/srep12017 · Cited by 56
Genetic and tissue-level analyses prioritize HDL-associated apolipoprotein M in psoriasis
Zha, S., Wang, W., Li, L., Wu, Y., Wang, X., & Sun, L. (2026) · Journal of Lipid Research · doi:10.1016/j.jlr.2026.101171
Metadata
- Authors
- Mehta, N. N., Li, R., Krishnamoorthy, P., Yu, Y., Farver, W., Rodrigues, A., Raper, A., Wilcox, M., Baer, A., DerOhannesian, S., Wolfe, M., Reilly, M. P., Rader, D. J., VanVoorhees, A., & Gelfand, J. M.
- Venue
- Atherosclerosis
- Publisher
- Elsevier BV
- Published
- 2012-09
- Volume
- 224
- Issue
- 1
- Pages
- 218-221
- ISSN
- 0021-9150 (ISSN-L)
- OpenAlex
- W1991793488
- Cited by
- 162
- References
- 3
- FWCI
- 10.82
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Abnormal lipoprotein particles and cholesterol efflux capacity in patients with psoriasis. https://app.cochat.ai/papers/10.1016/j.atherosclerosis.2012.06.068
- The paper
- Mehta, N. N., Li, R., Krishnamoorthy, P., Yu, Y., Farver, W., Rodrigues, A., Raper, A., Wilcox, M., Baer, A., DerOhannesian, S., Wolfe, M., Reilly, M. P., Rader, D. J., VanVoorhees, A., & Gelfand, J. M. (2012). Abnormal lipoprotein particles and cholesterol efflux capacity in patients with psoriasis. Atherosclerosis. https://doi.org/10.1016/j.atherosclerosis.2012.06.068
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.